Logo image of PYPD

POLYPID LTD (PYPD) Stock Fundamental Analysis

USA - NASDAQ:PYPD - IL0011326795 - Common Stock

3.335 USD
-0.04 (-1.04%)
Last: 9/26/2025, 8:25:03 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to PYPD. PYPD was compared to 196 industry peers in the Pharmaceuticals industry. PYPD has a bad profitability rating. Also its financial health evaluation is rather negative. PYPD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PYPD had negative earnings in the past year.
PYPD had a negative operating cash flow in the past year.
PYPD had negative earnings in each of the past 5 years.
PYPD had a negative operating cash flow in each of the past 5 years.
PYPD Yearly Net Income VS EBIT VS OCF VS FCFPYPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

PYPD's Return On Assets of -115.07% is on the low side compared to the rest of the industry. PYPD is outperformed by 78.06% of its industry peers.
PYPD has a worse Return On Equity (-377.67%) than 74.49% of its industry peers.
Industry RankSector Rank
ROA -115.07%
ROE -377.67%
ROIC N/A
ROA(3y)-141.15%
ROA(5y)-114.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PYPD Yearly ROA, ROE, ROICPYPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

PYPD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYPD Yearly Profit, Operating, Gross MarginsPYPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for PYPD has been increased compared to 1 year ago.
Compared to 5 years ago, PYPD has more shares outstanding
Compared to 1 year ago, PYPD has an improved debt to assets ratio.
PYPD Yearly Shares OutstandingPYPD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PYPD Yearly Total Debt VS Total AssetsPYPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -16.54, we must say that PYPD is in the distress zone and has some risk of bankruptcy.
PYPD has a worse Altman-Z score (-16.54) than 76.53% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that PYPD is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, PYPD is in line with its industry, outperforming 51.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -16.54
ROIC/WACCN/A
WACCN/A
PYPD Yearly LT Debt VS Equity VS FCFPYPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

PYPD has a Current Ratio of 1.31. This is a normal value and indicates that PYPD is financially healthy and should not expect problems in meeting its short term obligations.
PYPD has a Current ratio of 1.31. This is in the lower half of the industry: PYPD underperforms 71.94% of its industry peers.
A Quick Ratio of 1.31 indicates that PYPD should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.31, PYPD is not doing good in the industry: 66.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.31
PYPD Yearly Current Assets VS Current LiabilitesPYPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

PYPD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.06%, which is quite impressive.
EPS 1Y (TTM)62.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PYPD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.15% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.36%
EPS Next 2Y29.29%
EPS Next 3Y20.21%
EPS Next 5Y18.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PYPD Yearly Revenue VS EstimatesPYPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
PYPD Yearly EPS VS EstimatesPYPD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PYPD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PYPD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYPD Price Earnings VS Forward Price EarningsPYPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYPD Per share dataPYPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as PYPD's earnings are expected to grow with 20.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.29%
EPS Next 3Y20.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PYPD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POLYPID LTD

NASDAQ:PYPD (9/26/2025, 8:25:03 PM)

3.335

-0.04 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners38.25%
Inst Owner Change-95.08%
Ins Owners5.87%
Ins Owner ChangeN/A
Market Cap52.19M
Analysts82
Price Target12.75 (282.31%)
Short Float %0.27%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.66%
Min EPS beat(2)-21.92%
Max EPS beat(2)-19.4%
EPS beat(4)2
Avg EPS beat(4)-7.69%
Min EPS beat(4)-21.92%
Max EPS beat(4)5.63%
EPS beat(8)4
Avg EPS beat(8)4.15%
EPS beat(12)8
Avg EPS beat(12)6.4%
EPS beat(16)10
Avg EPS beat(16)4.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.35%
EPS NY rev (3m)-27.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.79
P/tB 6.79
EV/EBITDA N/A
EPS(TTM)-3.79
EYN/A
EPS(NY)-1.62
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS0
BVpS0.49
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.07%
ROE -377.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.15%
ROA(5y)-114.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.69%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.31
Altman-Z -16.54
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.45%
Cap/Depr(5y)86.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.6%
EPS Next Y49.36%
EPS Next 2Y29.29%
EPS Next 3Y20.21%
EPS Next 5Y18.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.43%
OCF growth 3YN/A
OCF growth 5YN/A